12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Feraheme regulatory update

AMAG said Swissmedic approved Rienso ferumoxytol to treat iron deficiency anemia in chronic kidney disease (CKD) patients. The IV iron replacement therapy is approved for the indication in the U.S. and Canada as Feraheme, and in the EU...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >